For your patients with newly diagnosed GBM,
Optune GioTM delivers the power of TTFields to attack GBM cells where they’re vulnerable1
A standard of care proven to provide long-term quality survival without adding systemic toxicity2-4,*
*Patient-reported data collected per EORTC QLQ-C30 at baseline and months 3, 6, 9, and 12. The 30-question survey covered 5 daily-functioning domains (Physical, Role, Social, Emotional, and Cognitive).
TTFields, Tumor Treating Fields
Discover the innovation of Optune Gio
Optune Gio is a wearable treatment delivery system that can provide continuous anti-cancer therapy†
Gill is an Optune Gio user and Patient Ambassador. Patient images reflect the health status of the patient at the time each photo was taken.
Optune Gio leverages biophysical principles to disrupt tumor viability
Explore how it delivers TTFields, which exert antitumor effects by disrupting activity of cancer cells during multiple phases of mitosis1
In newly diagnosed GBM,
Survival with Optune + TMZ vs TMZ alone was significantly higher at the 2-year landmark analysis and remained higher at 5 years2,5
Among patients with newly diagnosed GBM, more time on Optune Gio resulted in a significantly greater survival benefit7,‡
‡From a post hoc analysis.
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers include alternating electric fields (Optune Gio) as a Category 1 Preferred regimen, following maximal safe resection if feasible (or else biopsy), and standard radiation therapy with concurrent and adjuvant TMZ, for patients aged ≤70 years with newly diagnosed supratentorial GBM and good performance status regardless of MGMT promoter status.8,§
There is uniform NCCN consensus for this recommendation based on high-level evidence (Category 1), and superior efficacy, safety, evidence, and when appropriate, affordability (Preferred).8
§The NCCN defines good performance as Karnofsky Performance Score (KPS) ≥60. The trial on which the IFU is based used an eligibility criteria of KPS ≥70.2,8
National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Submit a prescription, and we take care of the rest
Personalized support from day one, from device training to reimbursement assistance and more
Find out more about how to start patients on Optune Gio
EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer core quality of life questionnaire; GBM, glioblastoma; KPS, Karnofsky Performance Score; MGMT, O-6-methylguanine-DNA methyltransferase; OS, overall survival; PFS, progression-free survival; TMZ, temozolomide.
References: 1. Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004;64(9):3288-3295. 2. Optune. Instructions For Use. Novocure; 2023. 3. Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of treatment with tumor-treating fields and health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA. 2018;4(4):495-504. 4. Novocure Data on File US-DOF-0035. 5. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306-2316. 6. Stupp R, Idbaih A, Steinberg DM, et al. Prospective, multicenter phase III trial of tumor treating fields together with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. Presented at: 2017 Annual Meeting of the American Association for Cancer Research; April 1-5, 2017; Washington, DC. Oral presentation LBA AACR CT007. 7. Toms SA, Kim CY, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. J Neurooncol. 2019;141(2):467-473. 8. Referenced with permission from NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers V.1.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed June 30, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org.